Live Breaking News & Updates on Biocryst Pharmaceuticals Company Profile

Stay updated with breaking news from Biocryst pharmaceuticals company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 30,130,000 shares, a decline of 31.8% from the October 15th total of 44,190,000 shares. Based on an average daily volume of 2,770,000 shares, […] ....

United States , Biocryst Pharmaceuticals Stock Performance , News Ratings For Biocryst Pharmaceuticals Daily , Jpmorgan Chase Co , Royal Bank , Biocryst Pharmaceuticals Inc , Metlife Investment Management , American Century Companies Inc , Jefferies Financial Group , Biocryst Pharmaceuticals Company Profile , Needham Company , York Mellon Corp , Biocryst Pharmaceuticals , Hedge Funds Weigh In On Biocryst Pharmaceuticals , Fairfield Bush , Get Free Report , New York Mellon Corp , Century Companies , Life Investment Management , Financial Group , Cryst Pharmaceuticals , Biocryst Pharmaceuticals Daily , Nasdaq Bcrx ,

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Buy" from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued a […] ....

United States , Lazard Asset Management , Analyst Recommendations For Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Stock Down , Jefferies Financial Group , Third Bancorp , News Ratings For Biocryst Pharmaceuticals Daily , Biocryst Pharmaceuticals , Fairfield Bush , Royal Bank , Advisory Services Network , Fifth Third Bancorp , Biocryst Pharmaceuticals Company Profile , Biocryst Pharmaceuticals Inc , Needham Company , Get Free Report , Marketbeat Ratings , Asset Management , Services Network , Cryst Pharmaceuticals Stock Down , Get Free , Cryst Pharmaceuticals , Biocryst Pharmaceuticals Daily , Nasdaq Bcrx ,

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Buy" from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued ratings on the stock in […] ....

News Ratings For Biocryst Pharmaceuticals Daily , Analyst Recommendations For Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Price Performance , Vanguard Group Inc , Biocryst Pharmaceuticals , Needham Company , Jefferies Financial Group , Institutional Investors Weigh In On Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Company Profile , Biocryst Pharmaceuticals Inc , Royal Bank , Get Free Report , Financial Group , Cryst Pharmaceuticals , Street Corp , Get Free , Biocryst Pharmaceuticals Daily , Nasdaq Bcrx ,

BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded at Royal Bank of Canada

Royal Bank of Canada upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a sector perform rating to an outperform rating in a report issued on Monday, MarketBeat.com reports. They currently have $10.00 price target on the biotechnology company’s stock, up from their prior price target of $9.00. A number of other research analysts […] ....

United States , Biocryst Pharmaceuticals Inc , Institutional Trading Of Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Company Profile , Advisory Services Network , Royal Bank , Needham Company , Jefferies Financial Group , Lazard Asset Management , Analyst Recommendations For Biocryst Pharmaceuticals , Biocryst Pharmaceuticals , News Ratings For Biocryst Pharmaceuticals Daily , Biocryst Pharmaceuticals Trading , Fairfield Bush , Free Report , Moderate Buy , Cryst Pharmaceuticals , Get Free Report , Services Network , Biocryst Pharmaceuticals Daily , Nasdaq Bcrx , Royal Bank Of Canada ,

BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Outperform at Royal Bank of Canada

Royal Bank of Canada upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a sector perform rating to an outperform rating in a report issued on Monday, Marketbeat.com reports. Royal Bank of Canada currently has $10.00 price target on the biotechnology company’s stock, up from their previous price target of $9.00. BCRX has been […] ....

United States , Royal Bank , Biocryst Pharmaceuticals Company Profile , Needham Company , Jefferies Financial Group , Analyst Recommendations For Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Inc , News Ratings For Biocryst Pharmaceuticals Daily , Advisory Services Network , Lazard Asset Management , Fairfield Bush , Biocryst Pharmaceuticals , Hedge Funds Weigh In On Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Price Performance , Free Report , Financial Group , Moderate Buy , Cryst Pharmaceuticals , Get Free Report , Services Network , Biocryst Pharmaceuticals Daily , Nasdaq Bcrx , Royal Bank Of Canada ,